<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722993</url>
  </required_header>
  <id_info>
    <org_study_id>ProGastro Kids 16</org_study_id>
    <nct_id>NCT02722993</nct_id>
  </id_info>
  <brief_title>Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of a probiotic product, when co-administered with antibiotics, on
      gastrointestinal symptoms following antibiotic treatment in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of loose/watery stools</measure>
    <time_frame>19-26 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antibiotic-associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children at the age of 1-11 years that have been prescribed antibiotic treatment.

          -  Problems with loose stools during earlier antibiotic treatments.

          -  Children whose parents or legal caregivers have signed the informed consent to
             participate in the study.

        Exclusion Criteria:

          -  Chronic intestinal disease, immunodeficiency or immunosuppressive treatment.

          -  Chronic or acute diarrheal disease.

          -  Use of laxatives the week before inclusion in the study.

          -  Antibiotic treatment for the last four weeks before inclusion in the study.

          -  Intake of probiotic products for the last two weeks before inclusion in the study.

          -  Known hypersensitivity to any of the ingredients in the probiotic product or the
             placebo (potato starch Â± bacterial culture that may contain traces of soy).

          -  Patient requiring hospitalisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>11 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Piotr Socha, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Memorial Health Institute, Warzaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marek Woynarowski, PhD</last_name>
    <phone>(+48 22) 612 45 73</phone>
    <email>m.woynarowski@med-net.pl</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 23, 2016</lastchanged_date>
  <firstreceived_date>March 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
